France: Marketing Authorization for: IASOglio® 2 GBq/mL, solution for injection
It is a pleasure to announce the Marketing Autorisation of IASOglio® 2 GBq/mL, solution for injection. We are proud to make available this pharmaceutical to patients suffering from brain tumor (glioma). IASOglio® is for the diagnostic use in Nuclear Medicine´s most state-of-the-art method, Positron Emission Tomography (PET).
“In previous years we have got 4 Marketing authorizations for PET-products enabling the diagnosis of different malignant processes in human body. We are happy to enhance one more effective approach in diagnosis of the cancer, this time with IASOglio®, tracer aimed for patients with glioma” emphasizes mag. Christoph Artner, Founder of IASON
In the next months, IASOglio® will become registered in other European countries (not just in France) and in this way, it will become available to all patients suffering from this aggressive tumour.